Gastric Cancer Market to Grow at a CAGR of 12.63% During 2024-2032, Aided by the Growth in Clinical Trials Across the 8 Major Markets

Gastric Cancer Market Overview

Gastric cancer or stomach cancer originates in the cells that line the stomach. Targeted therapies and chemotherapy are commonly recommended for the treatment of this cancer. The growing aging population and lifestyle-related factors including dietary habits and smoking are contributing to the rise in the cases of gastric cancer. The rising development of targeted therapies and immunotherapy such as pembrolizumab (Keytruda) and nivolumab (Opdivo) are expected to bolster the market growth. Moreover, the expansion of clinical trials for novel drugs and combination therapies is likely to shape the market landscape in the forecast period.

Key Findings

• Recent data suggests that older people are more susceptible to developing gastric cancer, with around 6 out of every 10 individuals diagnosed with the disease annually aged 65 or above. Thus, the growing elderly population is one of the primary drivers of the market.
• In November 2023, the FDA approved Merck’s combination therapy involving Keytruda (pembrolizumab) and chemotherapy as a first-line treatment for gastric cancer in adult patients based on the efficacy of the treatment to reduce mortality risk by 22% compared to chemotherapy alone. This shift towards combination therapies is a major market trend.
• The rising investment in oncology research and development and increased government initiatives to detect gastric cancer early are expected to elevate the market value in the forecast period.

Gastric Cancer Market Demand Drivers

Gastric cancer ranks as the second most common cause of cancer death worldwide, reflecting the need for effective treatments to combat the disease. In India, gastric cancer is reported as the fifth most common cancer in men while in women, it is the seventh most common cancer. The prevalence of gastric cancer is high in East Asian countries such as Japan where it causes significant mortality. For instance, in 2022, around 41,000 deaths occurred in Japan due to gastric cancer. Thus, the substantial burden of gastric cancer is driving the market demand for advanced therapies and diagnostics.

Gastric Cancer Market Segmentation Analysis

The Treatment Type Segment is Poised to Experience Significant Market Growth

Based on type, the market segmentation includes chemotherapy, immunotherapy, surgery, targeted drug therapy, and others. The surgery segment holds a high market value as it is one of the most effective treatments for early-stage gastric cancer. Surgery is a common treatment for localized gastric cancer and the advancements in minimally invasive procedures such as laparoscopic and robotic surgeries are further propelling the market growth. Additionally, the rising preference for the combination of surgery with other treatments like chemotherapy and radiation is poised to boost the demand for the segment.

The market report also offers insights based on cancer type, route of administration, end user, and region.

Gastric Cancer Market: Competitive Landscape

• In July 2024, Signet Therapeutics, a preclinical-stage biopharmaceutical company, announced the US Food and Drug Administration (FDA) had granted approval to its Investigational New Drug (IND) application for the first-ever targeted therapy for diffuse gastric cancer (DGC) called Sigx1094, which is discovered by artificial intelligence (AI) and validated by organoid disease models.
• In July 2024, Myricx Bio, a cancer therapy spinout from the Imperial and the Francis Crick Institute, secured USD 114 million in a Series A financing round to support the clinical development of its novel treatments based on antibody-drug conjugates (ADCs) for a range of different tumor types, including gastric cancer.
• Other players involved in the market include AstraZeneca, Myriad Genetics Inc., Pfizer, Inc., Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Celltrion, AbbVie Inc., and GSK plc., and Celltrion.

Gastric Cancer Market Analysis by Regional Overview

The United States Covers a Significant Market Share

The market report offers insight into various geographical locations, including the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States is a significant market for gastric cancer owing to the high demand for targeted therapies and the presence of leading companies driving growth and development in the market. The increasing aging population and patient access to advanced treatments are fuelling the market expansion. Additionally, the robust government funding for oncology research and increased public health initiatives promoting screening and prevention are likely to impact the market demand in the region.

Key Offerings of the Report

• The EMR report gives an overview of the market for gastric cancer for the time span of (2017-2023) and (2024-2032).
• The report also offers historical (2017-2023) and forecast (2024-2032) market information for the treatment type, cancer type, route of administration, end userend-user, and region of the market.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which is constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us:

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790